MetaCap

BioStem Technologies Inc. (BSEM)

NASDAQ: BSEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.6351-0.0724 (-10.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BSEM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$12.18M
52-week range
0.5347 – 8.40
Day range
0.5347 – 0.71
Volume / Avg
254.19K / 194.93K
Beta
—

52-week range

$0.5347$8.40

BSEM stock today

Shares of BioStem Technologies (BSEM) finished lower on Nov 20 at $0.6351, a drop of 10.23% or $0.0724 per share, versus the S&P 500's 3.70% decline. Shares are 92.4% below their 52-week high of $8.40, set on Jan 28, 2026 and 18.8% above the 52-week low of $0.5347, near the bottom of the past year's range. BSEM is down 83.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 84.0%.

BioStem Technologies trades at 0.7x its trailing twelve-month earnings per share of $0.88. Its forward P/E of 2.2x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About BioStem Technologies

Company profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
Fort Lauderdale, FL
Employees
73

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$7.00+1002.19%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.64 vs $-0.43
Surprise
-48.84%

BSEM news

All BSEM news

BioStem Technologies peers

Health Care sector
BSEM peer companies
CompanyPrice% ChgMarket capCompare
BCDABioCardia Inc.0.785+1.60%$11.88Mvs BSEM
PASGPassage Bio Inc.3.92+11.68%$12.61Mvs BSEM
DYAIDyadic International Inc.0.287-7.66%$11.51Mvs BSEM
ABOSAcumen Pharmaceuticals Inc.0.1865-3.52%$13.49Mvs BSEM
PLURPluri Inc.0.94-3.07%$13.51Mvs BSEM
ESLAEstrella Immunopharma Inc.0.321-5.70%$14.11Mvs BSEM
TCRXTScan Therapeutics Inc.0.1459+2.24%$9.89Mvs BSEM
ATYRaTyr Pharma Inc.3.82+3.52%$9.74Mvs BSEM

Indexes, lists and sector

BioStem Technologies stock FAQ

What is BioStem Technologies's stock price today?

BSEM last traded at $0.6351 as of Nov 20, 4:00 PM EST, down 10.23% on the day. Prices are delayed at least 15 minutes.

What is BSEM's P/E ratio?

BSEM trades at a trailing P/E ratio of 0.72 and a forward P/E of 2.19.

What is the BSEM 52-week high?

The 52-week high for BSEM is $8.40 and the 52-week low is $0.5347. The stock is currently 92.4% below its high.

Compare BSEM